Phenyl butyl nitrone compositions and methods for treatment of oxidative tissue damage

A composition for in vivo treatment of oxidative CNS tissue damage [resulting from ischemia or inflammation] not associated with bacterial toxins comprising:

• .alpha.-phenyl t-butyl nitrone [and derivatives] or a derivative thereof [having spin trapping activity and preventing ATP depletion in vivo in tissue] of the formula:
• ##STR16## X is phenyl or ##STR17## wherein R is H, ##STR18## and n is a whole integer from 1 to 5;
• or ##STR19## Y is a tert-butyl group that can be hydroxylated or acetylated on one or more positions;
• phenyl;
• or ##STR20## Z is a C.sub.1 to C.sub.5 straight or branched alkyl group [further comprising a compound selected from the group consisting of streptokinase, tissue plasminogen activator, mannitol and lazaroides]
• a pharmaceutically acceptable carrier for [intravenous] administration to a patient,
• wherein the .alpha.-phenyl nitrone is in an amount effective to prevent tissue damage [resulting from ischemia or inflammation] not associated with bacterial toxins wherein the nitrone [and further compound are] is present in effective amounts.

A composition comprising:

• nitrone compound of the formula:
• ##STR22## wherein:
• X is phenyl or ##STR23## wherein R is H, ##STR24## and n is a whole integer from 1 to 5;
• or ##STR25## Y is a tert-butyl group that can be hydroxylated or acetylated on one or more positions;
• phenyl;
• or ##STR26## wherein W is ##STR27## and Z is a C.sub.1 to C.sub.5 stright or branched alkyl group;
• subject to the proviso that X is not phenyl when Y is tert-butyl, in a pharmaceutically-acceptable, orally-administrable carrier. 8. The composition of claim 27 wherein Y is tert-butyl, X is ##STR28##
• and R is H.

A composition comprising:

• nitrone compound of the formula:
• ##STR30## wherein:
• X is phenyl or ##STR31## wherein R is H, ##STR32## and n is a whole integer from 1 to 5;
• or ##STR33## Y is a tert-butyl group that can be hydroxylated or acetylated on one or more positions;
• phenyl;
• or ##STR34## wherein W is ##STR35## and Z is a C.sub.1 to C.sub.5 straight or branched alkyl group;
• subject to the proviso that X is not phenyl when Y is tert-butyl in pharmaceutically-acceptable, intravenously-administrable carrier.